A Bill to require the Secretary of State to take steps to secure licences for off-patent drugs in new indications; to require the National Institute for Health and Care Excellence to conduct technology appraisals for off-patent drugs in new indications; and for connected purposes.
House of Commons
30 March 2015
May contain errors — check source documents for definitive information.
The Off-patent Drugs Bill would require the government to secure licences for off-patent medicines when they could be used for new medical indications. It would also require NICE to perform technology appraisals for those off-patent drugs in the new indications. The aim is to widen access to affordable medicines by expanding the approved uses of existing drugs.
The bill has reached the second reading in the House of Commons; the data provided does not show further progression beyond that stage.
Generated 21 February 2026
2 Jul 2014
7 Nov 2014
The Bill was presented to Parliament through the ballot procedure on 2 July 2014. This is known as the first reading and there was no debate on the Bill at this stage.
This Bill was stood over at its second reading on 7 November 2014 because fewer than 40 MPs were present.
The 2014-15 session of Parliament has prorogued and this Bill will make no further progress.
No recorded votes for this bill yet.
